
    
      The purpose of the post market clinical trial is to evaluate the safety and efficacy of the
      Cordimax Rapamycin Eluting Coronary Stent System (RECS). The Cordimax will be compared to an
      active control group represented by the FDA approved commercially available Abbott Vascular
      XIENCE V速 EECS Everolimus Eluting Coronary Stent System.

      The post market clinical trial consists of a randomized clinical trial (RCT) in China which
      will enroll approximately 3660 subjects (2:1 randomization Cordimax速 RECS : XIENCE V速 EECS)
      with a maximum of two de novo native coronary artery lesion treatment within vessel sizes >=
      2.5 mm and <= 4 mm.

      All subjects in the RCT will be screened per the protocol required inclusion/exclusion
      criteria. The data collected will be compared to data from the subjects enrolled into the
      XIENCE V速 arm of US RCT.

      All subjects will have clinical follow-up at 30, 60, 90days, and 1, 2, 3, 4, and 5 years so
      as to collect the needed data for the subsequent analysis.(Data collecting at 1st year will
      be conducted in the clinic in order to get the 12 lead ecg result once after out of the
      hospital) .
    
  